This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – September 13, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Dr. Reddy’s Laboratories (RDY - Snapshot Report), AstraZeneca (AZN - Analyst Report), Par Pharmaceutical Companies Inc. , Mylan Inc. (MYL - Analyst Report) and Watson Pharmaceuticals Inc. .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Dr. Reddy’s Launches Generic Toprol
Dr. Reddy’s Laboratories (RDY - Snapshot Report) recently announced the launch of its generic version of AstraZeneca’s (AZN - Analyst Report) hypertension drug Toprol XL (metoprolol succinate extended release) tablets in the US.
The company had received approval for its Abbreviated New Drug Application (ANDA) from the US Food & Drug Administration (FDA) in August 2012.
Subsequently, Dr. Reddy’s launched its generic version of Toprol XL tablets (25 mg, 50 mg, 100 mg and 200 mg) in the US on September 11, 2012.
Toprol XL is marketed for the treatment of hypertension, angina pectoris, heart failure and disturbances caused by cardiac rhythm, maintenance treatment following myocardial infarction and migraine prophylaxis.
According to IMS Health, US branded and generic sales of Toprol XL were approximately $1.13 billion for the twelve months ended June 30, 2012.
Currently, Par Pharmaceutical Companies Inc. markets the authorized generic version of AstraZeneca’s Toprol XL in the US. Apart from this, generic versions of Toprol XL are also marketed by Mylan Inc. (MYL - Analyst Report) and Watson Pharmaceuticals Inc..
Currently, we have a Neutral recommendation on Dr. Reddy’s. The stock carries a Zacks #3 Rank (short-term Hold rating).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339